Literature DB >> 1965034

Characterization of VIP- and helodermin-preferring receptors on human small cell lung carcinoma cell lines.

J Luis1, S I Said.   

Abstract

We investigated the molecular and pharmacologic characteristics of VIP receptors on two human SCLC cell lines: NCI-N592 and NCI-H345. With NCI-N592 cell, the order of potency of VIP-related peptides in inhibiting 125I-VIP binding and in stimulating cAMP production was typical of the human VIP receptor. By covalent cross-linking, a polypeptide of Mr 62,300 was obtained. Conversely, the behavior of NCI-H345 cell line was totally different: helodermin was the most potent peptide, VIP and PHI were equipotent, while hGRF and secretin were totally ineffective. These results suggest that NCI-N592 cells possess a typical VIP receptor while NCI-H345 cells possess a helodermin-preferring receptor, and that the natural target of helodermin might not be the VIP receptor.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1965034     DOI： 10.1016/0196-9781(90)90158-2

Source DB:  PubMed          Journal:  Peptides        ISSN： 0196-9781            Impact factor:   3.750


  7 in total

Review 1.  Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Authors:  Anthony J Harmar; Jan Fahrenkrug; Illana Gozes; Marc Laburthe; Victor May; Joseph R Pisegna; David Vaudry; Hubert Vaudry; James A Waschek; Sami I Said
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Evidence that the anti-spasmogenic effect of the beta-adrenoceptor agonist, isoprenaline, on guinea-pig trachealis is not mediated by cyclic AMP-dependent protein kinase.

Authors:  L Spicuzza; M G Belvisi; M A Birrell; P J Barnes; D J Hele; M A Giembycz
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

3.  Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo.

Authors:  K Maruno; A Absood; S I Said
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

4.  A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.

Authors:  T W Moody; F Zia; M Draoui; D E Brenneman; M Fridkin; A Davidson; I Gozes
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

5.  VPAC1 receptors and lung cancer.

Authors:  T W Moody; J Walters; M Casibang; F Zia; Y Gozes
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

Review 6.  International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.

Authors:  A J Harmar; A Arimura; I Gozes; L Journot; M Laburthe; J R Pisegna; S R Rawlings; P Robberecht; S I Said; S P Sreedharan; S A Wank; J A Waschek
Journal:  Pharmacol Rev       Date:  1998-06       Impact factor: 25.468

7.  Pituitary adenylate cyclase activating peptide receptors regulate the growth of non-small cell lung cancer cells.

Authors:  F Zia; M Fagarasan; K Bitar; D H Coy; J R Pisegna; S A Wank; T W Moody
Journal:  Cancer Res       Date:  1995-11-01       Impact factor: 12.701
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.